Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| 5-Amino-1MQ | Dihexa | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses. | Research indicates 10-20 mg daily via oral or sublingual administration. |
| Timing | Morning dosing preferred. Can be taken with or without food. | Morning dosing preferred. Can be taken with or without food (orally active). |
| Cycle Duration | 8-12 week cycles. | 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.
Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.
Morning dosing preferred. Can be taken with or without food.
8-12 week cycles.
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Research indicates 10-20 mg daily via oral or sublingual administration.
Morning dosing preferred. Can be taken with or without food (orally active).
2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →